About: Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19
Creator	Wang, Li Zhao, Lei Wang, Haijun Zhu, Rui Li, M Hu, Desheng Li, Mingyue Luo, Shanshan Dong, Yalan Du, Keye Fan, Heng Guo, Weina Tian, Chunxia Zhang, Zili Zhou, Haifeng
source	Elsevier; Medline; PMC
abstract	Abstract Background A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), outbroke in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stays, progression and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19. Methods 83 confirmed COVID-19 patients were divided into the CVD (n=42) and non-CVD (n=41) group according to their medical history. Medical records information including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT) as well as treatment measures were collected, analyzed and compared between two groups. Results COVID-19 patients with CVD showed: (1) more severe pathological changes in the lung, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactate dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK) and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD. Conclusions Our data indicated that CVD is a strong risk factor for a rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.
has issue date	2020-04-18(xsd:dateTime)
bibo:doi	10.1016/j.numecd.2020.04.013
bibo:pmid	32456948
has license	els-covid
sha1sum (hex)	ca2d65700dcef4081a5e02d1d1bc2432016979a8
schema:url	https://doi.org/10.1016/j.numecd.2020.04.013
resource representing a document's title	Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19
has PubMed Central identifier	PMC7165120
has PubMed identifier	32456948
schema:publication	Nutrition, metabolism, and cardiovascular diseases : NMCD
resource representing a document's body	covid:ca2d65700dcef4081a5e02d1d1bc2432016979a8#body_text
is schema:about of	named entity 'fibrinogen' named entity 'compared' named entity 'computed tomography' named entity 'alanine aminotransferase' named entity 'CRP' named entity 'GLUTAMYLTRANSFERASE' named entity 'COVID-19' named entity 'CONFIRMED' named entity 'SERUM AMYLOID A' named entity 'CVD' named entity 'MARKERS' named entity 'METHODS' named entity 'HYDROXYBUTYRATE DEHYDROGENASE' named entity 'GROUP' named entity 'BACKGROUND' covid:arg/ca2d65700dcef4081a5e02d1d1bc2432016979a8 named entity 'patients' named entity 'collected' named entity 'medical history' named entity 'divided' named entity 'compared' named entity 'dehydrogenase' named entity 'γ-glutamyltransferase' named entity 'SAA' named entity 'erythrocyte sedimentation rate' named entity 'serum' named entity 'COVID-19' named entity 'serum' named entity 'CVD' named entity 'virus' named entity 'LDH' named entity 'alanine aminotransferase' named entity 'coronavirus' named entity 'medical history' named entity 'serum ferritin' named entity 'prognosis' named entity 'SARS-CoV' named entity 'prognosis' named entity 'ground-glass opacity' named entity '4.7' named entity 'comorbidity' named entity 'underlying diseases' named entity 'missing data' named entity 'ACE2' named entity 'COVID' named entity 'risk of death' named entity 'infection' named entity 'fever' named entity 'viral pneumonia' named entity 'critically ill' named entity 'ARDS' named entity 'risk factor' named entity 'retrospective study' named entity 'cough' named entity 'hypercoagulable state' named entity 'data analysis' named entity 'inflammation' named entity 'multiple organ failure' named entity 'ACEI' named entity 'tissue injury' named entity 'underlying diseases' named entity 'CT images' named entity 'prognosis' named entity 'CVD' named entity 'CVD' named entity 'risk factor' named entity 'lymphocyte count'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software